Bristol Myers Squibb Shares Fall 2% After Patient Death in MS Trial
Bristol Myers Squibb disclosed a patient death in its early-stage Breakfree-2 study of experimental CAR T therapy zolacabtagene autoleucel for multiple sclerosis. Its shares fell 2% on Friday.